AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02417597 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Description: Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.
Study NCT02840097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Active drug is provided to participants as described based on the TXA arm they are randomized to.
Study NCT02840097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline is provided to participants if randomized to this treatment arm.
Study NCT00819611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Working memory training
Description: 15 minutes of working memory training, 5 days a week for a period of 5 weeks
Study NCT00819611 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control version of Cogmed working memory training
Description: 15 minutes of 'sham' working memory training, 5 days a week for a period of 5 weeks
Study NCT02665520 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liposuction for retrieval of own stem cells from fat cells
Study NCT02937909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of wound care products from a single manufacturer
Description: The participating Healthcare Professionals will be asked to use BSN medical wound care products for the study duration
Study NCT02577510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve Injection- Nerve Stimulator
Description: For the neurostimulation nerve injection technique, the initial puncture site will be located medial to the anterosuperior iliac spine, just caudal to the inguinal ligament \[7\]. The 22-gauge insulated needle will be connected to a stimulator set at a current of 1.5 mA, a pulse width of 300 ms and a frequency of 2 Hz. A paresthesia referred to the lateral aspect of the thigh at a minimal stimulatory threshold of 0.6 mA (0.3ms) will be sought prior to the injection of local anesthetic \[7\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
Study NCT02577510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve Injection - Ultrasound
Description: For the ultrasound nerve injection group, after skin disinfection, the inguinal region of patients will be scanned using a high-frequency (6 to 13 MHz) linear array transducer covered with a sterile plastic cover. An ultrasound image showing the inguinal ligament and anterior superior iliac spine (ASIS) will be obtained. Using an out-of-plane technique, a 22-gauge nerve block needle will be inserted 1-2 cm medial to ASIS. The needle will be advanced until its tip rests under the inguinal ligament, immediately ventral to the iliopsoas muscle \[6\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
Study NCT04334031 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Biobanking with genetic analysis
Description: Patients included in the IMMINeNT cohort will be collected 7 blood samples for the research project at each revaluation visit. For patients who accepted, genetic analysis (DNA analysis) will be done on a part of those samples.
Study NCT04203394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Exercise Group
Description: 12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise
Study NCT04203394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Group
Description: Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
Study NCT04377308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine 20 mg to 60 mg daily given from 2 weeks to 2 months duration
Study NCT00840229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triamcinolone hexacetonide
Description: 20 mg
Study NCT00840229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide
Description: 1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
Study NCT00840229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone hexacetonide
Description: 1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
Study NCT04449718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200,000 IU on admission
Study NCT02128958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF102
Description: orally q12h
Study NCT02128958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally q12 hours
Study NCT03073200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT02961868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal and supra-aortic trunks vascular imaging
Description: Abdominal and supra-aortic trunks vascular imaging (angiography, CT-angiography or MR-angiography) will be performed 3 years after inclusion. This imaging will be compare to initial imaging (which is a part of usual care, not an intervention added by the study) in order to assess FMD progression.
Study NCT02961868 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sampling (genetic)
Description: A sample of blood will be taken to meet the objective of estimating the rate of genetic polymorphism that may influence disease progression or be associated with complications.
Study NCT02961868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling (biomarkers)
Description: A sample of blood will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
Study NCT02961868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine sampling
Description: A sample of urine will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
Study NCT03073200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03073200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered SC
Study NCT04384705 — intervention group
Intervention type: OTHER
Intervention: research specific blood sample
Description: * one blood sample before the epidemic phase~* one blood sample during epidemic phase~* one blood sample after epidemic phase
Study NCT02277691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536TCH tablet
Description: TAK-536TCH tablets
Study NCT02277691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536CCB tablet
Description: TAK-536CCB tablets
Study NCT02277691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCTZ 12.5 mg tablet
Description: HCTZ tablets
Study NCT03688334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen 40 %
Description: Oxygen supplementation (40%) via Venturi mask
Study NCT03688334 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Medical air (sham O2)
Description: Medical air supplementation via Venturi mask
Study NCT01625611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone 100 mg titrated over one week
Study NCT02645136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Pilates exercises
Study NCT02645136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT and AES
Description: conventional pelvic floor muscle exercises combined with anal electrical stimulation Device: electrical stimulation (Dualpex 961 Uro®)
Study NCT01222442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Single dose, oral inhalation
Study NCT02087995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: A prescribed clinic session day for participating subjects.
Study NCT01723579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate (NOMAC)
Description: Oral tablet with daily release of 2.5 mg
Study NCT01723579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Description: Daily release of 1.5 mg
Study NCT01222442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single dose, oral encapsulated tablet
Study NCT01222442 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Single dose, oral inhalation
Study NCT02338024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Antiretroviral Treatment Access Study intervention
Study NCT04334031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF-12 questionnaire
Description: Patients included in the IMMINeNT cohort will be asked to complete SF-12 quality of life questionnaire.
Study NCT03284944 — intervention group
Intervention type: DEVICE
Intervention: Small-Volume
Description: Small-volume (2 - 3 mL soft-draw Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.
Study NCT03284944 — intervention group
Intervention type: DEVICE
Intervention: Standard-Volume
Description: Standard-volume (4 - 6 mL Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.
Study NCT00786149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varenicline plus Motivational Interviewing counseling
Description: Motivational Interviewing; 8 weeks of counseling
Study NCT01449617 — intervention group
Intervention type: DRUG
Intervention: Aspirin plus clopidogrel
Description: Clopidogrel, will be started 48 hours before the procedure with a loading dose of of 300mg and continued at 75mg/day.~Aspirin will be given at the dose of 100-325mg/day.
Study NCT04436289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Link
Description: In the Home Link intervention, a team will conduct home visits to (1) provide a structured clinical assessment; (2) reconcile medications, (3) provide psychosocial support through patient-centered counseling, and (4) assess home needs (food security). These visits will start one week after discharge and be repeated every two weeks until the participant is stabilized and ready to initiate lower intensity clinic-based services or three months have elapsed.
Study NCT00645034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo by mouth as a single dose
Study NCT00645034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 100 mg by mouth as a single dose
Study NCT00645359 — intervention group
Intervention type: PROCEDURE
Intervention: diffusion MRI
Description: Diffusion MRI involves using MRI scanning to measure water transport at the cellular level. In this study, dMRI is being used to measure the response of tumors to chemotherapy.
Study NCT00785200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Chlorhexidine-soaked disposable cloths will be distributed each Monday, Wednesday, and Friday to each enrolled detainee for a 6-month period.
Study NCT00785200 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water-soaked disposable wash cloths identical in appearance to the CHG cloths will be distributed to enrolled detainees on every Monday, Wednesday, and Friday for a 6-month period.
Study NCT02036177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCu300A IUB intrauterine device
Description: Spherical copper IUD
Study NCT02036177 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T380A IUD
Description: T-shaped copper IUD
Study NCT01125124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nitrate
Description: Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.
Study NCT01125124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Nitrate
Description: Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.
Study NCT03150446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flexible cystoscopy
Description: After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy. If the stent was well-placed, the flexible cystoscope was withdrawn. If the double-J stent was not visualized in the bladder, the surgeon pushed the stent inferiorly using a laparoscopic instrument and monitor A until the stent came out through the ureteral orifice on monitor B.
Study NCT03355534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine
Description: drug is intravenously infused to patients
Study NCT03355534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal dexmedetomidine
Description: drug is nasally given to patients
Study NCT03355534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous saline
Description: saline is given to patients intravenously
Study NCT03355534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous saline
Description: saline is given to patients intravenously
Study NCT03355534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal saline
Description: normal saline is given to patients nasally
Study NCT03355534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nasal saline
Description: normal saline is given to patients nasally
Study NCT00786149 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline without counseling
Description: Brief advice, one time during initial session
Study NCT03298789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activation exercise
Description: Two series of 4 activation exercise will be included in the intervention.
Study NCT03298789 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 7 series of static stretching
Description: 7 series of 4 20 seconds static stretches will be conducted.
Study NCT02161081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myocardial CT perfusion
Description: Adenosine-stress dynamic myocardial CT perfusion using 128-slice dual-source CT
Study NCT03298789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7 series of static stretching
Description: 7 series of 4 20 seconds static stretches will be conducted.
Study NCT02645136 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT01266070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: 500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).
Study NCT03619642 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Robotic assessment of finger proprioception
Description: The assessment will be performed using a robotic device specifically designed for the assessment of finger proprioception at the metacarpophalangeal (MCP) joint .
Study NCT02766517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Administered topically
Study NCT03821181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC group
Description: Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
Study NCT03821181 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
Study NCT01366950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intelligent physical activity
Description: 30 minutes of moderate activity 6 days a week and 45 minutes of high intensity training 1 day a week. Moderate activity is monitored in diaries and high intensity training is monitored by a trainer.
Study NCT01439009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Once-daily oral administration of one tolvaptan 15 mg tablet in the morning
Study NCT01439009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of tolvaptan
Description: Once-daily oral administration of one placebo tablet in the morning
Study NCT02590250 — intervention group
Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
Study NCT04399044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic muscle flap
Description: A muscle flap refers to taking an expendable muscle with its vascular supply and moving it to a new area. In this case, the investigators will take a muscle from the leg or abdomen that is redundant (other muscles perform the same function) and moving it to cover vascular grafts to provide healthy tissue to prevent infection.
Study NCT03511326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl Aminolaevulinate 16% Cream
Description: Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy
Study NCT00482807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Study NCT00482807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00482807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Study NCT00482807 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study NCT03259659 — intervention group
Intervention type: OTHER
Intervention: ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index
Description: In this study, an electrocardiogram signal will be recorded for 30 min in the fasting state, and blood samples for inflammatory cytokines analysis (7 ml) will be taken at the end of the ECG recording; fecal samples will be taken on the experimental day before the study. In addition, ulcerative colitis disease activity index will be assessed using the Mayo scoring system.
Study NCT03183336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge split interpositional block graft
Study NCT03183336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: decortication Onlay block graft
Study NCT00525447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40
Description: 2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.
Study NCT00525447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Up to 25 mg daily of a 21-day cycle.
Study NCT00525447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg administered weekly.
Study NCT04688892 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cupping
Description: dynamic cupping
Study NCT03868150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone Injection
Description: Patients stratified into the amiodarone study group were administered amiodarone until day of discharge. Amiodarone administration began intraoperatively with the administration of a 150 mg IV amiodarone loading bolus prior to separation from coronary pulmonary bypass, followed by 1 mg/min IV amiodarone for six hours (360 mg), then 0.5 mg/min IV amiodarone for 18 hours (540 mg), then transitioned to 400 mg oral amiodarone twice a day until discharge. In total, patients in the amiodarone treatment group received 1,050mg of IV amiodarone plus 800mg/day of oral amiodarone thereafter until discharge.
Study NCT03868150 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amiodarone Injection
Description: Patients stratified into the amiodarone study group were administered amiodarone until day of discharge. Amiodarone administration began intraoperatively with the administration of a 150 mg IV amiodarone loading bolus prior to separation from coronary pulmonary bypass, followed by 1 mg/min IV amiodarone for six hours (360 mg), then 0.5 mg/min IV amiodarone for 18 hours (540 mg), then transitioned to 400 mg oral amiodarone twice a day until discharge. In total, patients in the amiodarone treatment group received 1,050mg of IV amiodarone plus 800mg/day of oral amiodarone thereafter until discharge.
Study NCT03868150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative Rapid Atrial Pacing
Description: Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.